On Oct. 29, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.

For this age group, the vaccine was to be administered in a two-dose regimen of 10-ﾵg doses given 21 days apart. The 10-ﾵg dose level was carefully selected based on safety, tolerability and immunogenicity data. This is the first COVID-19 vaccine authorized in the U.S. for individuals 5 through 11 years of age.